4//SEC Filing
La Barge Joseph 4
Accession 0000899243-19-029413
CIK 0001609351other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 4:27 PM ET
Size
18.7 KB
Accession
0000899243-19-029413
Insider Transaction Report
Form 4
La Barge Joseph
See remarks
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2019-12-17−11,250→ 0 totalExercise: $40.44Exp: 2026-01-04→ Common Stock (11,250 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2019-12-17−35,000→ 0 totalExercise: $42.73Exp: 2029-01-15→ Common Stock (35,000 underlying) - Disposition from Tender
Common Stock
2019-12-17$114.50/sh−50,193$5,747,099→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2019-12-17−12,500→ 0 totalExercise: $56.17Exp: 2027-01-17→ Common Stock (12,500 underlying) - Disposition from Tender
Common Stock
2019-12-17$114.50/sh−200$22,900→ 0 total(indirect: Held by Reporting Person's immediate family members) - Disposition to Issuer
Stock Option (Right to Buy)
2019-12-17−21,000→ 0 totalExercise: $50.55Exp: 2028-01-17→ Common Stock (21,000 underlying) - Disposition to Issuer
Restricted Stock Units
2019-12-17−19,500→ 0 totalExercise: $0.00→ Common Stock (19,500 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
- [F2]Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
- [F3]Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).
Documents
Issuer
Spark Therapeutics, Inc.
CIK 0001609351
Entity typeother
Related Parties
1- filerCIK 0001673526
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 4:27 PM ET
- Size
- 18.7 KB